BCC and Erivedge®: disease burden and impact on quality of life

Advanced basal cell carcinoma (BCC) can be disfiguring, debilitating or even fatal.

The burden of BCC can have a substantial physical and psychological impact on patients5,6
 

  • Locally advanced BCC that are large or destructive, in critical and/or functionally sensitive areas in the head and neck region and recur frequently, are difficult to treat and can result in considerable patient morbidity with surgical or radiation therapy1,2,7
  • The functional and cosmetic impact of locally advanced BCC and associated treatments have a direct effect on health-related quality of life, behaviour and social activities, emotional wellbeing and mental health5,6

 

Accurate and consistent assessment of lesion and patient factors can help determine appropriate treatment options:
 

  • Patient age, comorbidities, concomitant medications, prior BCC treatment history, performance status, recurrent lesions or the presence of Gorlin syndrome may impact choice of treatment1,2
  • Surgery or radiotherapy may not be indicated for locally invasive BCC lesions where it would result in disfigurement or loss of organ function, or where it would result in deformity due to size or number of lesions1,2

 

Erivedge® treatment is associated with long-term clinically meaningful improvements in health-related quality of life, particularly in the emotional wellbeing of the patient8
 

  • STEVIE showed that Erivedge® treatment was associated with clinically meaningful improvements in health-related quality of life in patients with locally advanced or metastatic BCC using Skindex-16 and MD Anderson Symptom Inventory assessments8
  • Treatment with Erivedge® was consistently associated with clinically meaningful improvements (≥10-point improvements in Skindex-16) at all time points in emotion domain scores in patients with locally advanced BCC8

 

Erivedge® is a standard of care in advanced BCC inappropriate for surgery or radiotherapy, with studies in more than 2,000 patients in clinical trials and more than 5 years’ clinical practice experience9–13

 

 

References

 

1. Lear JT et al. Br J Cancer 2014;111:1476–1481. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200081/

2. Peris K et al. Future Oncol 2015;11:703–712. Abstract available: https://www.ncbi.nlm.nih.gov/pubmed/25686123

3. Amici JM et al. Eur J Dermatol 2015;25:586–594. Abstract available at: https://link.springer.com/article/10.1684/ejd.2015.2641

4. Mohan SV et al. Curr Dermatol Rep 2014;3:40–45. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931971/

5. Steenrod AW et al. Dermatol Ther (Heidelb) 2015;5:183–199. Available at: https://link.springer.com/content/pdf/10.1007%2Fs13555-015-0081-6.pdf

6. Mathias SD et al. JAMA Dermatol 2014;150:169–176. Available at: https://jamanetwork.com/journals/jamadermatology/fullarticle/1784338

7. Peris K et al. Eur J Cancer 2019;118:10–34. Available at: https://www.ejcancer.com/article/S0959-8049(19)30362-4/pdf

8. Hansson J et al. Eur J Dermatol 2018;28:775–783. Abstract available at: https://link.springer.com/article/10.1684/ejd.2018.3448

9. Basset-Séguin N et al. Eur J Cancer 2017;86:334–348. Available at: https://www.ejcancer.com/article/S0959-8049(17)31247-9/fulltext

10. Sekulic A et al. N Engl J Med 2012;366:2171–2179. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278761/

11. Sekulic A et al. J Eur Acad Dermatol Venereol 2017;31(suppl 3):42,FC3.5. Available at: https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3286-5

12. Sofen H et al. J Am Acad Dermatol 2015;73:99–105. Available at: https://www.jaad.org/article/S0190-9622(15)01395-X/pdf

13. Dréno B et al. Lancet Oncol 2017;18:404–412. Available at: https://www.jaad.org/article/S0190-9622(15)01395-X/pdf